Olpasiran significantly reduces apoB-associated oxidised phospholipids (OxPL-apoB), according to results of a pre-specified analysis of data from the Phase 2 OCEAN(a)-DOSE trial.
Other articles available on Lp(a) Forum
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.